Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Chronic Anemia Cured by Gene Therapy Using Genetically Engineered Blood Vessels

By BiotechDaily International staff writers
Posted on 29 Nov 2011
A novel gene therapeutic method employing genetically engineered blood vessels to deliver erythropoietin (EPO) to anemic mice was described in a proof-of-concept study.

Investigators at Harvard Medical School (Boston, MA, USA) created a new type of blood vessel by isolating endothelial colony-forming cells from human blood and then inserting into these cells the gene that encodes EPO. The gene that was inserted was part of a complex that included an “off/on switch” activated by the drug doxycycline.

The genetically engineered colony-forming cells were injected under the skin of immunodeficient mice that had been rendered anemic by radiation treatment (as often occurs in cancer patients) or through loss of kidney tissue (modeling chronic kidney failure).

Results published in the November 17, 2011, issue of the journal Blood revealed that the transplanted cells spontaneously formed networks of blood vessels that became integrated into the animals' own circulatory system. EPO produced by the genetically engineered cells was then released directly into the bloodstream. EPO production could be controlled by administrating or withholding doxycycline.

“Blood-vessel implants are an ideal platform technology for gene therapy applications whose goal is systemic drug delivery,” said senior author Dr. Juan M. Melero-Martin, assistant professor of surgery at Harvard Medical School. “Blood vessels are one of the few tissues where we have good control over engraftment. Endothelial cells are easily isolated from blood, are good at assembling themselves into blood vessels, and are ideal for releasing compounds into the bloodstream, since they line the blood vessels.”

“Such drugs are currently made in bioreactors by engineered cells, and are very expensive to make in large amounts. The paradigm shift here is, why we do not instruct your own cells to be the factory?” said Dr. Melero-Martin.

If this approach can be applied in humans, it would relieve patients from having to receive frequent EPO injections, thus reducing the medical costs associated with the management of anemia.

Related Links:
Harvard Medical School


RANDOX LABORATORIES
BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.